EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

Returns on capital

EyePoint Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-75.8%

avg -170.5%

ROIC

-74.5%

avg -51.9%

ROA

-63.7%

avg -49.3%

Analysis

ROA is currently the strongest return metric at -63.7% versus its period average of -49.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jay S. Duker

President, Chief Executive Officer & DirectorUSD 1.35M670<0.01%

George O. Elston

Executive Vice President & Chief Financial OfficerUSD 904.8K61——

Ramiro Ribeiro

Chief Medical OfficerUSD 888.56K430<0.01%

David Scott Jones

Senior Vice PresidentUSD 672.08K580<0.01%

Tarek S. Hassan

Senior VP & Chief Strategic Science Officer————

Michael Campbell

Chief Commercial Officer————

Michael J. Maciocio

Chief Manufacturing Officer————

Ron I. Honig

Chief Legal Officer & Company Secretary————

Isabelle Lefebvre

Chief Regulatory Officer————

Jennifer Leonard

Chief People Officer & Senior Vice President of IT————

Marcia Sellos-Moura

Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$71,981.80

Sells

10

$2.01M

Net Transaction Value

−$1.94M

Net selling

Most Active

Ribeiro Ramiro

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 18, 26

Zaderej Karen L.

Direct

Buy$52.3K
Jun 30, 26

Ribeiro Ramiro

Direct

Sell$36.6K
Jun 30, 26

Ribeiro Ramiro

Direct

Sell$36.6K
Apr 17, 26

Ribeiro Ramiro

Direct

Sell$36.6K
Mar 16, 26

Duker Jay S.

Indirect

Buy$19.7K
Mar 4, 26

Ribeiro Ramiro

Direct

Sell$43.6K
Feb 17, 26

Ribeiro Ramiro

Direct

Sell$36.6K
Jan 5, 26

Ribeiro Ramiro

Direct

Sell$727.3K
Dec 4, 25

Cormorant Asset Management, LP

Indirect

Sell$942.2K
Dec 4, 25

Lurker Nancy

Direct

Sell$140.5K

1–10 of 12

Summary

Insiders reported 2 buys worth $71,981.80 and 10 sells worth $2.01M over the last 12 months. That adds up to net selling of $1.94M. Ribeiro Ramiro was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A-8.8%
+81.7% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Recent growth has been strongest in Revenue at -8.8% over three years. Forward estimates point to Revenue at +81.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does EyePoint Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about EYPT's management, answered from reported figures.

Who manages EYPT?

EyePoint Pharmaceuticals, Inc. (EYPT) lists 11 active executives. The top listed executive is Tarek S. Hassan, Senior VP & Chief Strategic Science Officer.

Are EYPT insiders buying or selling?

Recent insider activity shows net buying of $41.41M.